Oragenics Inc (OGEN) stock
OGENNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.20−0.15 (-42.59%)
Close on Nov 13, 2026Market cap $906.90KP/E –Yield –
Oragenics r&d expenses
Research and development expenses are spending on new products and technology.
Oragenics's R&D Expenses for the twelve months ending Sep 30, 2026 was $4.07M, up 20.1% year over year. For fiscal 2025 it was $2.39M, down 41.8% from the year before. Over ten years it grew -12.1% a year on average. The highest annual figure on record is $22.11M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.39M | -41.8% |
| FY2024 | Dec 31, 2024 | $4.11M | -73.4% |
| FY2023 | Dec 31, 2023 | $15.49M | +53.8% |
| FY2022 | Dec 31, 2022 | $10.07M | -4.9% |
| FY2021 | Dec 31, 2021 | $10.59M | -52.1% |
| FY2020 | Dec 31, 2020 | $22.11M | +82.4% |
| FY2019 | Dec 31, 2019 | $12.12M | +103.0% |
| FY2018 | Dec 31, 2018 | $5.97M | +68.7% |
| FY2017 | Dec 31, 2017 | $3.54M | -25.6% |
| FY2016 | Dec 31, 2016 | $4.75M | -45.6% |
| FY2015 | Dec 31, 2015 | $8.73M | +184.9% |
| FY2014 | Dec 31, 2014 | $3.07M | -67.3% |
| FY2013 | Dec 31, 2013 | $9.36M | +19.1% |
| FY2012 | Dec 31, 2012 | $7.86M | +221.0% |
| FY2011 | Dec 31, 2011 | $2.45M | +21.6% |
| FY2010 | Dec 31, 2010 | $2.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.58M | +69.3% |
| Q2 FY2026 | Jun 30, 2026 | $1.18M | +161.7% |
| Q1 FY2026 | Mar 31, 2026 | $645.47K | +89.0% |
| Q4 FY2025 | Dec 31, 2025 | $670.54K | -59.7% |
| Q3 FY2025 | Sep 30, 2025 | $930.89K | +5.9% |
| Q2 FY2025 | Jun 30, 2025 | $449.68K | -50.4% |
| Q1 FY2025 | Mar 31, 2025 | $341.54K | -48.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.67M | -84.9% |
| Q3 FY2024 | Sep 30, 2024 | $879.04K | +14.3% |
| Q2 FY2024 | Jun 30, 2024 | $906.78K | -54.8% |
| Q1 FY2024 | Mar 31, 2024 | $663.41K | -60.3% |
| Q4 FY2023 | Dec 31, 2023 | $11.04M | +682.1% |
| Q3 FY2023 | Sep 30, 2023 | $769.35K | -72.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.01M | -22.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.67M | -49.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.41M | +7.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.78M | -21.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.59M | +5.0% |
| Q1 FY2022 | Mar 31, 2022 | $3.29M | +1.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.31M | -60.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.55M | +1.4% |
| Q2 FY2021 | Jun 30, 2021 | $2.47M | -78.6% |
| Q1 FY2021 | Mar 31, 2021 | $3.26M | -12.2% |
| Q4 FY2020 | Dec 31, 2020 | $3.35M | +21.5% |
| Q3 FY2020 | Sep 30, 2020 | $3.50M | +14.0% |
| Q2 FY2020 | Jun 30, 2020 | $11.54M | +197.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.71M | +53.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.76M | +53.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.07M | +94.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.88M | +205.1% |
| Q1 FY2019 | Mar 31, 2019 | $2.41M | +82.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.79M | +120.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.58M | +58.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.27M | +110.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.33M | +18.2% |
| Q4 FY2017 | Dec 31, 2017 | $815.31K | -54.1% |
| Q3 FY2017 | Sep 30, 2017 | $996.48K | – |
| Q2 FY2017 | Jun 30, 2017 | $605.41K | – |
| Q1 FY2017 | Mar 31, 2017 | $1.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.78M | – |
See a number that looks wrong?